{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:28:29Z","timestamp":1791858509069,"version":"4.3.4"},"reference-count":48,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.1188\/21.onf.151-160","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T13:21:48Z","timestamp":1613654508000},"page":"151-160","source":"Crossref","is-referenced-by-count":22,"title":["A Qualitative Study of the Experiences of Living With Multiple Myeloma"],"prefix":"10.1188","volume":"48","author":[{"given":"Matthew","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Leak Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2020). Cancer Statistics Center: Myeloma. https:\/\/cancerstatisticscenter.cancer.org\/?_ga=2.121553931.226068755.152..."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G.J., & Crowley, J. (2014). Curing myeloma at last: Defining criteria and providing the evidence. Blood, 124(20), 3043\u20133051. https:\/\/doi.org\/10.1182\/blood-2014-07-552059","DOI":"10.1182\/blood-2014-07-552059"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Carlsen, K., Dalton, S.O., Frederiksen, K., Diderichsen, F., & Johansen, C. (2007). Are cancer survivors at an increased risk for divorce? A Danish cohort study. European Journal of Cancer, 43(14), 2093\u20132099. https:\/\/doi.org\/10.1016\/j.ejca.2007.05.024","DOI":"10.1016\/j.ejca.2007.05.024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Cormican, O., & Dowling, M. (2016). Managing relapsed myeloma: The views of patients, nurses and doctors. European Journal of Oncology Nursing, 23, 51\u201358. https:\/\/doi.org\/10.1016\/j.ejon.2016.04.003","DOI":"10.1016\/j.ejon.2016.04.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cormican, O., & Dowling, M. (2018). Living with relapsed myeloma: Symptoms and self-care strategies. Journal of Clinical Nursing, 27(7\u20138), 1713\u20131721. https:\/\/doi.org\/10.1111\/jocn.14232","DOI":"10.1111\/jocn.14232"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Brill, I.K., Omel, J., Godby, K., Kumar, S.K., & Brown, E.E. (2017). Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances, 1(4), 282\u2013287. https:\/\/doi.org\/10.1182\/bloodadvances.2016002493","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Hari, P.N., & Kumar, S.K. (2016). Differences between unselected patients and participants in multiple myeloma clinical trials in US: A threat to external validity. Leukemia and Lymphoma, 57(12), 2827\u20132832. https:\/\/doi.org\/10.3109\/10428194.2016.1170828","DOI":"10.3109\/10428194.2016.1170828"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Dahan, J.F., & Auerbach, C.F. (2006). A qualitative study of the trauma and posttraumatic growth of multiple myeloma patients treated with peripheral blood stem cell transplant. Palliative and Supportive Care, 4(4), 365\u2013387. https:\/\/doi.org\/10.1017\/S1478951506060470","DOI":"10.1017\/S1478951506060470"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Dusetzina, S.B., Huskamp, H.A., & Keating, N.L. (2019). Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA, 321(20), 2025\u20132027. https:\/\/doi.org\/10.1001\/jama.2019.4492","DOI":"10.1001\/jama.2019.4492"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Fulton, J.J., LeBlanc, T.W., Cutson, T.M., Porter Starr, K.N., Kamal, A., Ramos, K., . . . Williams, J.W. (2019). Integrated outpatient palliative care for patients with advanced cancer: A systematic review and meta-analysis. Palliative Medicine, 33(2), 123\u2013134. https:\/\/doi.org\/10.1177\/0269216318812633","DOI":"10.1177\/0269216318812633"},{"key":"11","unstructured":"Gasparetto, C., & Sivaraj, D. (2019). Understanding multiple myeloma. Jones and Bartlett Learning."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hsieh, H.F., & Shannon, S.E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277\u20131288. https:\/\/doi.org\/10.1177\/1049732305276687","DOI":"10.1177\/1049732305276687"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kane, R.C., Bross, P.F., Farrell, A.T., & Pazdur, R. (2003). Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist, 8(6), 508\u2013513. https:\/\/doi.org\/10.1634\/theoncologist.8-6-508","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kelly, M., & Dowling, M. (2011). Patients\u2019 lived experience of myeloma. Nursing Standard, 25(28), 38\u201344. https:\/\/doi.org\/10.7748\/ns2011.03.25.28.38.c8397","DOI":"10.7748\/ns2011.03.25.28.38.c8397"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kent, E.E., Ambs, A., Mitchell, S.A., Clauser, S.B., Smith, A.W., & Hays, R.D. (2015). Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage. Cancer, 121(5), 758\u2013765. https:\/\/doi.org\/10.1002\/cncr.29119","DOI":"10.1002\/cncr.29119"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kumar, S. (2017). Emerging options in multiple myeloma: Targeted, immune, and epigenetic therapies. Hematology, 2017(1), 518\u2013524. https:\/\/doi.org\/10.1182\/asheducation-2017.1.518","DOI":"10.1182\/asheducation-2017.1.518"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kumar, S.K., Callander, N.S., Alsina, M., Atanackovic, D., Biermann, J.S., Castillo, J., . . . Shead, D.A. (2018). NCCN Guidelines Insights: Multiple myeloma, version 3.2018. Journal of the National Comprehensive Cancer Network, 16(1), 11\u201320. https:\/\/doi.org\/10.6004\/jnccn.2018.0002","DOI":"10.6004\/jnccn.2018.0002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Laviana, A.A., Luckenbaugh, A.N., & Resnick, M.J. (2020). Trends in the cost of cancer care: Beyond drugs. Journal of Clinical Oncology, 38(4), 316\u2013322. https:\/\/doi.org\/10.1200\/jco.19.01963","DOI":"10.1200\/JCO.19.01963"},{"key":"19","doi-asserted-by":"crossref","unstructured":"LeBlanc, M.R., Hirschey, R., Leak Bryant, A., LeBlanc, T.W., & Smith, S.K. (2020). How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review. Quality of Life Research, 29(6), 1419\u20131431. https:\/\/doi.org\/10.1007\/s11136-019-02392-6","DOI":"10.1007\/s11136-019-02392-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lin, Q., Zhao, J., Song, Y., & Liu, D. (2019). Recent updates on CAR T clinical trials for multiple myeloma. Molecular Cancer, 18, 154. https:\/\/doi.org\/10.1186\/s12943-019-1092-1","DOI":"10.1186\/s12943-019-1092-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Maher, K., & de Vries, K. (2011). An exploration of the lived experiences of individuals with relapsed multiple myeloma. European Journal of Cancer Care, 20(2), 267\u2013275. https:\/\/doi.org\/10.1111\/j.1365-2354.2010.01234.x","DOI":"10.1111\/j.1365-2354.2010.01234.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"McCullough, K.B., Hobbs, M.A., Abeykoon, J.P., & Kapoor, P. (2018). Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Current Hematologic Malignancy Reports, 13(2), 114\u2013124. https:\/\/doi.org\/10.1007\/s11899-018-0443-0","DOI":"10.1007\/s11899-018-0443-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"McNeely, M.L., Dolgoy, N., Onazi, M., & Suderman, K. (2016). The interdisciplinary rehabilitation care team and the role of physical therapy in survivor exercise. Clinical Journal of Oncology Nursing, 20(6, Suppl.), S8\u2013S16. https:\/\/doi.org\/10.1188\/16.CJON.S2.8-16","DOI":"10.1188\/16.CJON.S2.8-16"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Molassiotis, A., Wilson, B., Blair, S., Howe, T., & Cavet, J. (2011). Living with multiple myeloma: Experiences of patients and their informal caregivers. Supportive Care in Cancer, 19(1), 101\u2013111. https:\/\/doi.org\/10.1007\/s00520-009-0793-1","DOI":"10.1007\/s00520-009-0793-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Morgan, G.J., & Rasche, L. (2017). Where are we now with the treatment of multiple myeloma? Nature Reviews Clinical Oncology, 14, 461\u2013462. https:\/\/doi.org\/10.1038\/nrclinonc.2017.82","DOI":"10.1038\/nrclinonc.2017.82"},{"key":"26","unstructured":"National Cancer Institute. (2020). Cancer stat facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"27","unstructured":"National Comprehensive Cancer Network. (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Multiple myeloma (v.3.202021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Nielsen, L.K., Jarden, M., Andersen, C.L., Frederiksen, H., & Abildgaard, N. (2017). A systematic review of health-related quality of life in longitudinal studies of myeloma patients. European Journal of Haematology, 99(1), 3\u201317. https:\/\/doi.org\/10.1111\/ejh.12882","DOI":"10.1111\/ejh.12882"},{"key":"29","unstructured":"Patton, M.Q. (2015). Qualitative research and evaluation methods: Integrating theory and practice (4th ed.). Sage."},{"key":"30","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V. (2016). Updated diagnostic criteria and staging system for multiple myeloma. American Society of Clinical Oncology Educational Book, 36, e418\u2013e423. https:\/\/doi.org\/10.14694\/edbk_159009","DOI":"10.14694\/EDBK_159009"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V. (2018). Value and cost of myeloma therapy. American Society of Clinical Oncology Educational Book, 38, 662\u2013666. https:\/\/doi.org\/10.1200\/edbk_200867","DOI":"10.1200\/EDBK_200867"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Ramsenthaler, C., Kane, P., Gao, W., Siegert, R.J., Edmonds, P.M., Schey, S.A., & Higginson, I.J. (2016). Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis. European Journal of Haematology, 97(5), 416\u2013429. https:\/\/doi.org\/10.1111\/ejh.12790","DOI":"10.1111\/ejh.12790"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Ravi, P., Kumar, S.K., Cerhan, J.R., Maurer, M.J., Dingli, D., Ansell, S.M., & Rajkumar, S.V. (2018). Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal, 8(3), 26. https:\/\/doi.org\/10.1038\/s41408-018-0065-8","DOI":"10.1038\/s41408-018-0065-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Raza, S., Safyan, R.A., & Lentzsch, S. (2017). Immunomodulatory drugs (IMiDs) in multiple myeloma. Current Cancer Drug Targets, 17(9), 846\u2013857. https:\/\/doi.org\/10.2174\/1568009617666170214104426","DOI":"10.2174\/1568009617666170214104426"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Richardson, P., Roy, A., Acharyya, S., Panneerselvam, A., Mendelson, E., G\u00fcnther, A., . . . Einsele, H. (2017). Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: The case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Review of Hematology, 10(10), 933\u2013939. https:\/\/doi.org\/10.1080\/17474086.2017.1369399","DOI":"10.1080\/17474086.2017.1369399"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Rothwell, P.M. (2005). External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d. Lancet, 365(9453), 82\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(04)17670-8","DOI":"10.1016\/S0140-6736(04)17670-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Samala, R.V., Valent, J., Noche, N., & Lagman, R. (2019). Palliative care in patients with multiple myeloma. Journal of Pain and Symptom Management, 58(6), 1113\u20131118. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.07.014","DOI":"10.1016\/j.jpainsymman.2019.07.014"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Sengsayadeth, S., Malard, F., Savani, B.N., Garderet, L., & Mohty, M. (2017). Posttransplant maintenance therapy in multiple myeloma: The changing landscape. Blood Cancer Journal, 7(3), e545. https:\/\/doi.org\/10.1038\/bcj.2017.23","DOI":"10.1038\/bcj.2017.23"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Siegel, R.L., Miller, K.D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","DOI":"10.3322\/caac.21590"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., . . . Barlogie, B. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341(21), 1565\u20131571. https:\/\/doi.org\/10.1056\/nejm199911183412102","DOI":"10.1056\/NEJM199911183412102"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Stephens, C., Westmaas, J.L., Kim, J., Cannady, R., & Stein, K. (2016). Gender differences in associations between cancer-related problems and relationship dissolution among cancer survivors. Journal of Cancer Survivorship, 10(5), 865\u2013873. https:\/\/doi.org\/10.1007\/s11764-016-0532-9","DOI":"10.1007\/s11764-016-0532-9"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Takano, N., Ariyasu, R., Koyama, J., Sonoda, T., Saiki, M., Kawashima, Y., . . . Nishio, M. (2019). Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995\u20132017. Lung Cancer, 131, 69\u201377. https:\/\/doi.org\/10.1016\/j.lungcan.2019.03.008","DOI":"10.1016\/j.lungcan.2019.03.008"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Vlossak, D., & Fitch, M.I. (2008). Multiple myeloma: The patient\u2019s perspective. Canadian Oncology Nursing Journal, 18(3), 141\u2013151. https:\/\/doi.org\/10.5737\/1181912x183141145","DOI":"10.5737\/1181912x183141145"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Voorhees, P.M., Kaufman, J.L., Laubach, J., Sborov, D.W., Reeves, B., Rodriguez, C., . . . Richardson, P.G. (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood, 136(8), 936\u2013945.","DOI":"10.1182\/blood.2020005288"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Waks, A.G., & Winer, E.P. (2019). Breast cancer treatment: A review. JAMA, 321(3), 288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","DOI":"10.1001\/jama.2018.19323"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Wilson, I.B., & Cleary, P.D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59\u201365.","DOI":"10.1001\/jama.1995.03520250075037"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Wu, C. (2018). Systemic therapy for colon cancer. Surgical Oncology Clinics of North America, 27(2), 235\u2013242.","DOI":"10.1016\/j.soc.2017.11.001"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Yu, L., Norton, S., & McCracken, L.M. (2017). Change in \u201cself-as-context\u201d (\u201cperspective-taking\u201d) occurs in acceptance and commitment therapy for people with chronic pain and is associated with improved functioning. Journal of Pain, 18(6), 664\u2013672. https:\/\/doi.org\/10.1016\/j.jpain.2017.01.005","DOI":"10.1016\/j.jpain.2017.01.005"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/48\/2\/qualitative-study-experiences-living-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:48Z","timestamp":1763754588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/48\/2\/qualitative-study-experiences-living-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1188\/21.onf.151-160","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}